News

PRAN

Understanding the Impact of Clinical Trials on Shareholder Value

Andrew Klips | Equities.com |

Clinical trial data can move a stock price like virtually nothing else on Wall Street. Given the proclivity for volatility, investing in small- and mid-cap biotech is definitely not for the faint


Wall Street Rallies as Stocks Gain on Less Hawkish Yellen

Michael Teague | Equities.com |

Wall Street rallied early in Monday’s session, and maintained gains consistently throughout trading, with all indices once again approaching intraday highs to end the first quarter of 2014.


Prana Shares Plunge on Alzheimer’s Disease Drug Trial

Andrew Klips | Equities.com |

Shares of Prana Biotechnology (PRAN) are getting shellacked in premarket trading on Monday following the results of a mid-stage clinical trial of experimental drug PBT2 for Alzheimer’s


Benchmark Indices Remain Flat as Nasdaq Jumps to Open Week of Trading

Michael Teague | Equities.com |

Stocks mostly dawdled in Tuesday trading, though the Nasdaq managed to add two-thirds of a percent by the closing bell, as investors had only the anemic reading from the Empire State Manufacturing


Prana Biotechnology (PRAN) Skyrockets on Huntington's Disease Treatment

Joel Anderson | Equities.com |

Prana Biotechnology (PRAN) saw shares skyrocket as much 45 percent on Tuesday after the company returned data from a double-blind Phase II study for the efficacy of its experimental drug PBT2, a


Prana Biotechnology (PRAN) Continues Upward on Alzheimer's Disease Drug News

Andrew Klips | Equities.com |

Four trading days ago, shares of Prana Biotechnology Ltd. (PRAN) were trading a $4 each. A little jump ahead on Thursday was followed by a surge on Friday that has continued in early Monday



Discover: Trending Events

United Nations
Blockchain for Europe
Humanity 2.0
World Economic Forum